GlassScriptPhysician profile
Jason W Booth
NPI 1861460495
$6,758.78
in general payments reported to CMS, 2019-2025
47 companies · $1,858 in 2025
The $1,858 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $861 · 2021: $106 · 2022: $447 · 2023: $1,593 · 2024: $1,703 · 2025: $1,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,059 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,059.46 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $876.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $841.52 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $702.16 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $482.36 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $423.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medicure Pharma INC. | $299.33 | 2020 | |
| Lilly USA, LLC | $294.16 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $279.72 | 2023-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $258.80 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.93 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $232.91 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $164.56 | 2019-2025 | Shingrix, Trelegy Ellipta, Pediarix |
| Allergan, INC. | $162.45 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $155.62 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.26 | 2022-2025 | Xifaxan, Trulance |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.